Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Twist Bioscience Corp — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Twist Bioscience Corp for 27 Days on average.
| HYG | TWST | |
|---|---|---|
Market Cap | $17.89B | $10.08B |
Volume | 44,866,592 | 4,229,037 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $205.00 |
52-Week Low | $76.90 | $25.45 |
Typical Hold Time | 60 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.14, down 0.05% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with key support at $77. Recent dividends include $0.44 paid September 4, 2026. News highlights bond market volatility as Treasury yields reach multi-year highs, impacting high-yield corporate bonds.
Outlook remains cautious amid rising interest rates and bond market stress. The fund faces headwinds from higher borrowing costs but offers income through dividends. Key risks include further yield increases and economic slowdown affecting corporate credit quality.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
